WALTHAM, Mass. — October 2, 2025 — Leads & Copy — Dyne Therapeutics, Inc. (Nasdaq: DYN) has appointed Brian Posner to its Board of Directors, bringing 35 years of executive, investment, and board leadership expertise to the company. The company is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases.
Jason Rhodes, chairman of Dyne’s Board of Directors, noted Posner is joining during a pivotal phase as Dyne transitions to becoming a fully integrated biotechnology company poised to commercialize its first potential product in 2027. John Cox, president and CEO of Dyne, said Posner’s expertise will further strengthen the Board.
Posner is the founder and president of Point Rider Group (UK) Ltd. He currently serves as a director of Arch Capital Group and has previously chaired the AQR Funds and Bioverativ, and served as a director of Biogen, Sotheby’s and The Mutual Fund Store.
Dyne Therapeutics is developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease.
Contacts:
Investors:
Mia Tobias
ir@dyne-tx.com
781-317-0353
Media:
Stacy Nartker
snartker@dyne-tx.com
781-317-1938
Source: Dyne Therapeutics
